Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Biomedical Textiles Market Size, Share & Trends Analysis Report By Fiber Type (Biodegradable, Non-Biodegradable), By Fabric Type (Non-Woven, Woven, Others), By Application (Non-Implantable, Surgical Sutures, Others), By End-User, By Region, And Segment Forecasts, 2024-2031

The Biomedical Textiles Market Size is valued at USD 15.07 Billion in 2023 and is predicted to reach USD 26.85 Billion by the year 2031 at a 7.69 % CAGR during the forecast period for 2024-2031. Key Industry Insights & Findings from the report: The growing aging population, their spending on health and their demand for biomedical textiles has given rise the biomedical textiles market. The rapid growth in the aging population and medical ...

ID: 1480 180 Pages February 2025

Next-Generation Contraceptives Market Size, Share & Trends Analysis Distribution by Gender (Male, Female), End User (Hospital Pharmacies, Retail Pharmacies, Online Channels), Offering (Drugs, Devices), and Segment Forecasts, 2024-2031

Next-Generation Contraceptives Market Size is predicted to exhibit an 8.2% CAGR during the forecast period for 2024-2031. Next-generation contraceptives represent a promising frontier in reproductive health, containing a diverse array of innovative methods designed to prevent pregnancy effectively. For men, ongoing research includes the development of hormonal and non-hormonal options such as a pill that inhibits fertility by blocking vitamin ...

ID: 2534 180 Pages February 2025

Liposomal Vitamins and Minerals Market Forecast with Size and Share Analysis 2025 to 2034

Global Liposomal Vitamins and Minerals Market Size is predicted to raise at a 6.4% CAGR during the forecast period for 2024 to 2031. Liposomal Vitamins and Minerals Market Size, Share & Trends Analysis Report By Product Type (Vitamins (Vitamin C, Vitamin A, Vitamin B12, Vitamin E, Vitamin K, Combinations (Vitamin B Complex, Vitamin D3 & K2, Others), Minerals (Iron (Fe), Magnesium (Mg), Zinc (Zn), Others), Collagen, Glutathione, Curcumin,...

ID: 2914 180 Pages December 2024

Gene-to-Patient Market Report with Forecast 2025 to 2034

Global Gene-to-Patient Market Size is valued at USD 134.6 billion in 2023 and is predicted to reach USD 341.4 billion by the year 2031 at a 12.5% CAGR during the forecast period for 2024 to 2031. Gene-to-Patient Market Size, Share & Trends Analysis Report By Type (Gene Therapy, Gene Editing, Gene Silencing), By Application (Cancer Treatment, Genetic Disorders, Cardiovascular Diseases, Rare Diseases, Infectious Diseases), By End-user (Hospita...

ID: 2905 180 Pages November 2024

Digital Psychotherapeutics Market Size, Share & Trends Analysis Report, By Type (Mobile Apps, Online Platforms, Virtual Reality, Wearable Devices), By Indication (Phobias and Anxiety Disorders, Psychotic Disorders), By Business Model, By Application, By End User, By Region, Forecasts, 2024-2031

The Global Digital Psychotherapeutics Market Size is valued at USD 1.27 billion in 2023 and is predicted to reach USD 8.47 billion by the year 2031 at a 26.90% CAGR during the forecast period for 2024-2031.   The use of digital technology, software apps, and digital platforms to deliver evidence-based therapy interventions for mental health issues is referred to as digital psychotherapeutics, also known as digital therapies for m...

ID: 1876 180 Pages November 2024

Coronavirus Vaccine Market Size, Share & Trends Analysis Report By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, and MERS-CoV), Vaccine Type (Inactivated coronavirus vaccine, Live attenuated coronavirus vaccine, S-Protein based coronavirus vaccine), Region, And Segment Forecasts, 2023-2031.

The Coronavirus Vaccine Market is expected to grow at a -12.0 % CAGR during the forecast period for 2024-2034. Coronavirus Disease (COVID-19) is caused by coronavirus. Coronavirus is a type of virus which causes respiratory illness in humans and can causes serious illness in geriatric population (Mainly those with diabetes, chronic respiratory disease, cardiovascular disease, and cancer). Out of the seven types of coronavirus, SARS-CoV-2 is th...

ID: 1019 180 Pages November 2024

Idiopathic Pulmonary Fibrosis Management Market Size, Share and Growth Analysis 2026 to 2035

Global Idiopathic Pulmonary Fibrosis Management Market Size is valued at USD 3,113.5 Mn in 2023 and is predicted to reach USD 3,429.6 Mn by the year 2031 at a 1.28% CAGR during the forecast period for 2024 to 2031. Idiopathic Pulmonary Fibrosis Management Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib, Interferon Gammato1b, Others), By Treatment (Oxygen Therapy, Lung Transplant), By Route of Administration...

ID: 2885 180 Pages November 2024

Softwall Cleanrooms Market Size, Share & Trends Analysis Report By End-user (Pharmaceutical Industry, Biotechnology Industry, Medical Device Manufacturers, Hospitals) And Segment Forecasts, 2023-2031

The Global Softwall Cleanrooms Market Size is predicted to record at a 5.24% CAGR during the forecast period for 2023-2031. Manufacturing requirements for semiconductors, medical devices, and other products are cleaned in softwall cleanrooms. The need for cleanrooms rises as a result of the control they offer over environmental factors like temperature and the possibility of particle entry. A regulated environment where product contamination i...

ID: 1784 180 Pages November 2024

Sprycel Market Size, Share & Trends Analysis Report By Demographic (Age, Gender, Income), By Psychographic (Lifestyle, Attitudesa), By Behavioral, (Usage Rate, Compliance, Treatment), By Medical (Indication, Disease Stage), By Region, And By Segment Forecasts, 2023-2031.

The Sprycel Market Size is valued at USD 5.47 Bn in 2022 and is predicted to reach USD 8.52 Bn by the year 2031 at a 5.2% CAGR during the forecast period for 2023-2031. One of the effective cancer drugs is Sprycel. Adults with some significant forms of leukaemia (cancer of the white blood cells) are treated with it. Adult patients should use SPRYCEL® (dasatinib) for therapy. Newly discovered chronic myeloid leukaemia (CML) in the chronic p...

ID: 2041 180 Pages November 2024

CIN and HR-HPV Treatment Market Size, Share & Trends Analysis Report By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering, Product Type, and End User, Region And Segment Forecasts, 2023-2031

Global CIN And HR-HPV Treatment Market Size is valued at USD 11.48 billion in 2022 and is predicted to reach USD 20.08 billion by the year 2031 at a 6.5% CAGR during the forecast period for 2023-2031. CIN and HR-HPV treatment Cervical infection with human papillomavirus type 16 (HR-HPV 16) is a key risk factor for cervical intraepithelial neoplasia and a sexually transmitted disease. The most significant cause of cervical cancer is the human p...

ID: 2044 180 Pages November 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.